APG Asset Management US’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
– Sell
-25,728
Closed -$2.86M – 104
2025
Q3
$2.86M Hold
25,728
– – 0.02% 91
2025
Q2
$2.87M Hold
25,728
– – 0.02% 87
2025
Q1
$2.86M Hold
25,728
– – 0.02% 89
2024
Q4
$2.38M Sell
25,728
-3,237
-11% -$291K 0.02% 93
2024
Q3
$2.43M Sell
28,965
-340,161
-92% -$26M 0.02% 89
2024
Q2
$25.3M Buy
369,126
+8,006
+2% +$534K 0.15% 82
2024
Q1
$26.3M Buy
361,120
+116,854
+48% +$8.99M 0.15% 81
2023
Q4
$19.8M Buy
+244,266
New +$19M 0.12% 71

Other funds holding GILD

APG Asset Management US's GILD Position: Q4 2025 in Review

APG Asset Management US sold out of Gilead Sciences (GILD) in Q4 2025, closing a stake of 25,728 shares — an estimated $2.86M sold.

APG Asset Management US first reported a position in GILD in Q4 2023 and held it in 8 quarters. The position peaked at $26.3M in Q1 2024. 2,227 funds tracked by Wall St. Rank hold GILD as of Q4 2025.

  • APG Asset Management US reported no remaining Gilead Sciences position as of Q4 2025 after selling out during the quarter.
  • APG Asset Management US sold 25,728 Gilead Sciences shares in Q4 2025, an estimated $2.86M.
  • APG Asset Management US first reported a position in Gilead Sciences in Q4 2023 and held it in 8 quarters.
  • APG Asset Management US's Gilead Sciences position peaked at $26.3M in Q1 2024.
  • 2,227 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2025.

Based on APG Asset Management US's 13F filing for Q4 2025, filed 12 Feb 2026.